Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJLK1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:57:32 ON 25 JUN 2008

=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CAPLUS' ENTERED AT 13:57:55 ON 25 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Jun 2008  VOL 148 ISS 26
FILE LAST UPDATED: 24 Jun 2008  (20080624/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> S Weidner/AU
L1             3 WEIDNER/AU

=> S WEIDNER, M?/AU
L2           202 WEIDNER, M?/AU

=> S WEIDNER, MOR?/AU
L3            23 WEIDNER, MOR?/AU

=> S L3 and fatty acid ester
          403584 FATTY
              14 FATTIES
          403588 FATTY
```

```
                (FATTY OR FATTIES)
       4602225 ACID
       1633381 ACIDS
       5115521 ACID
                (ACID OR ACIDS)
        622412 ESTER
        457196 ESTERS
        863791 ESTER
                (ESTER OR ESTERS)
         30540 FATTY ACID ESTER
                (FATTY(W)ACID(W)ESTER)
L4           5 L3 AND FATTY ACID ESTER

=> D TI TOTAL

L4   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Treatment of cutaneous neurogenic inflammation

L4   ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Novel complexes of fatty acid esters of
     polyhydroxyalkanes and pyridine carboxy derivatives

L4   ANSWER 3 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Dihydro-triterpenes in the treatment of viral infections, cardiovascular
     disease, inflammation, hypersensitivity or pain

L4   ANSWER 4 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Use of esters of polyhydric alcohols to enhance the oral bioavailability
     of drug substances as well as novel esters and pharmaceutical compositions
     containing them

L4   ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   A method of rendering organic compounds soluble in fatty systems, novel
     chemical complexes of such compounds and various applications of the
     complexes


=> D 2 IBIB ABS

L4   ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:2715  CAPLUS
DOCUMENT NUMBER:          140:53415
TITLE:                    Novel complexes of fatty acid
                          esters of polyhydroxyalkanes and pyridine
                          carboxy derivatives
INVENTOR(S):              Weidner, Morten Sloth
PATENT ASSIGNEE(S):       Astion Development A/S, Den.
SOURCE:                   PCT Int. Appl., 70 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------          ----   --------    -------------------    --------
     WO 2004000333        A1    20031231    WO 2003-DK423          20030620
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
```

TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2491871	A1	20031231	CA 2003-2491871	20030620
AU	2003240441	A1	20040106	AU 2003-240441	20030620
EP	1560589	A1	20050810	EP 2003-729915	20030620
EP	1560589	B1	20061004		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN	1674921	A	20050928	CN 2003-819661	20030620
JP	2005537238	T	20051208	JP 2004-514590	20030620
EP	1640011	A1	20060329	EP 2005-19961	20030620

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

AT	341334	T	20061015	AT 2003-729915	20030620
NZ	537783	A	20061222	NZ 2003-537783	20030620
ES	2274236	T3	20070516	ES 2003-729915	20030620
NO	2005000309	A	20050318	NO 2005-309	20050119
US	20060069131	A1	20060330	US 2005-517592	20050815
HK	1076395	A1	20061124	HK 2005-110210	20051115

PRIORITY APPLN. INFO.:	DK 2002-951	A	20020620
	US 2002-389879P	P	20020620
	EP 2003-729915	A3	20030620
	WO 2003-DK423	W	20030620

OTHER SOURCE(S): MARPAT 140:53415

AB The present invention relates to novel combinations of fatty acid derivs. and pyridine carboxy derivs., including fatty acid esters with glycerol and 3-carboxy pyridine derivs. such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed herein.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> SEL RN 2
E1 THROUGH E29 ASSIGNED

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.92	20.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.80	-0.80

FILE 'REGISTRY' ENTERED AT 14:00:47 ON 25 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JUN 2008 HIGHEST RN 1030471-05-6
DICTIONARY FILE UPDATES: 24 JUN 2008 HIGHEST RN 1030471-05-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> S E1-E29
             1 59-67-6/BI
               (59-67-6/RN)
             1 10417-94-4/BI
               (10417-94-4/RN)
             1 107-88-0/BI
               (107-88-0/RN)
             1 110-86-1/BI
               (110-86-1/RN)
             1 114-33-0/BI
               (114-33-0/RN)
             1 124-07-2/BI
               (124-07-2/RN)
             1 141-22-0/BI
               (141-22-0/RN)
             1 142-62-1/BI
               (142-62-1/RN)
             1 143-07-7/BI
               (143-07-7/RN)
             1 329-89-5/BI
               (329-89-5/RN)
             1 334-48-5/BI
               (334-48-5/RN)
             1 373-49-9/BI
               (373-49-9/RN)
             1 4314-66-3/BI
               (4314-66-3/RN)
             1 4621-66-3/BI
               (4621-66-3/RN)
             1 463-40-1/BI
               (463-40-1/RN)
             1 50-70-4/BI
               (50-70-4/RN)
             1 502-54-5/BI
               (502-54-5/RN)
             1 506-26-3/BI
               (506-26-3/RN)
             1 513-85-9/BI
               (513-85-9/RN)
             1 544-63-8/BI
               (544-63-8/RN)
             1 544-64-9/BI
               (544-64-9/RN)
             1 56-81-5/BI
               (56-81-5/RN)
             1 57-10-3/BI
               (57-10-3/RN)
             1 57-55-6/BI
               (57-55-6/RN)
             1 60-33-3/BI

(60-33-3/RN)
1 6217-54-5/BI
(6217-54-5/RN)
1 6556-11-2/BI
(6556-11-2/RN)
1 7150-23-4/BI
(7150-23-4/RN)
1 98-92-0/BI
(98-92-0/RN)

L5 29 (59-67-6/BI OR 10417-94-4/BI OR 107-88-0/BI OR 110-86-1/BI OR 114-33-0/BI OR 124-07-2/BI OR 141-22-0/BI OR 142-62-1/BI OR 143-07-7/BI OR 329-89-5/BI OR 334-48-5/BI OR 373-49-9/BI OR 4314-66-3/BI OR 4621-66-3/BI OR 463-40-1/BI OR 50-70-4/BI OR 502-54-5/BI OR 506-26-3/BI OR 513-85-9/BI OR 544-63-8/BI OR 544-64-9/BI OR 56-81-5/BI OR 57-10-3/BI OR 57-55-6/BI OR 60-33-3/BI OR 6217-54-5/BI OR 6556-11-2/BI OR 7150-23-4/BI OR 98-92-0/BI)

=> D SCAN

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN myo-Inositol, hexa-3-pyridinecarboxylate
MF C42 H30 N6 O12
CI COM

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):28

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxamide, N-ethyl-
MF C8 H10 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,3-Butanediol
MF C4 H10 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9,12,15-Octadecatrienoic acid, (9Z,12Z,15Z)-
MF C18 H30 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxamide, 6-amino-
MF C6 H7 N3 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9-Octadecenoic acid, 12-hydroxy-, (9Z,12R)-
MF C18 H34 O3
CI COM

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyridine
MF C5 H5 N
CI COM, RPS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9,12-Octadecadienoic acid (9Z,12Z)-
MF C18 H32 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Hexadecanoic acid
MF C16 H32 O2
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-
MF C20 H30 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)-
MF C22 H32 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9-Tetradecenoic acid, (9Z)-

MF C14 H26 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)-
MF C18 H30 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9-Hexadecenoic acid, (9Z)-
MF C16 H30 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Dodecanoic acid
MF C12 H24 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Octanoic acid
MF C8 H16 O2

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3-Butanediol
MF C4 H10 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxylic acid
MF C6 H5 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,2,3-Propanetriol
MF C3 H8 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxamide, 6-methoxy-
MF C7 H8 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarbothioamide
MF C6 H6 N2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Tetradecanoic acid
MF C14 H28 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Octanoic acid, 2,3-dihydroxypropyl ester
MF C11 H22 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Decanoic acid
MF C10 H20 O2

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Hexanoic acid
MF C6 H12 O2
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxamide, N-methyl-
MF C7 H8 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pyridinecarboxamide
MF C6 H6 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,2-Propanediol
MF C3 H8 O2

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 29 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN D-Glucitol
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT
MF C6 H14 O6
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> S L5 and (C6 H6 N2 O/MF or C11 H22 O4/MF)
320 C6 H6 N2 O/MF
626 C11 H22 O4/MF
L6 2 L5 AND (C6 H6 N2 O/MF OR C11 H22 O4/MF)

=> D 1-2

L6 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 502-54-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN Octanoic acid, 2,3-dihydroxypropyl ester (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Octanoin, 1-mono- (7CI, 8CI)
OTHER NAMES:
CN (±)-Glycerol monoctanoate
CN α-Monocaprylin
CN 1-Monocaprylin
CN 1-Monocapryloyl-rac-glycerol
CN 1-Monooctanoin
CN 1-Monooctanoylglycerol
CN 2,3-Dihydroxypropyl octanoate
CN Caprylic acid α-monoglyceride
CN DL-1-Monooctanoin
CN Glyceryl 1-monooctanoate
CN Monoctanoin
CN Octanoic acid 1-monoglyceride
DR 19670-49-6

MF C11 H22 O4
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, MRCK*, RTECS*, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

108 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
109 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L6 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 98-92-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3-Pyridinecarboxamide (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nicotinamide (8CI)
OTHER NAMES:
CN β-Pyridinecarboxamide
CN 3-(Aminocarbonyl)pyridine
CN 3-Amidopyridine
CN 3-Carbamoylpyridine
CN 3-Pyridinecarboxylic acid amide
CN Aminicotin
CN Benicot
CN Delonin Amide
CN Dipegyl
CN m-(Aminocarbonyl)pyridine
CN NAM
CN Niacinamide
CN Niavit PP
CN Nicamina
CN Nicamindon
CN Nicasir
CN Nicobion
CN Nicofort
CN Nicosan 2
CN Nicosylamide
CN Nicotilamide
CN Nicotine acid amide
CN Nicotinic acid amide
CN Nicotinic amide
CN Nicotylamide
CN Nicovit
CN Nicovitina
CN Nictoamide
CN Niocinamide
CN Niozymin
CN NSC 13128
CN NSC 27452
CN Papulex
CN Pelmin

CN Pelmine
CN Pelonin amide
CN Vi-Nicotyl
CN Vitamin B
CN Vitamin B3
DR 123574-63-0, 37321-14-5, 78731-47-2
MF C6 H6 N2 O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10416 REFERENCES IN FILE CA (1907 TO DATE)
441 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10437 REFERENCES IN FILE CAPLUS (1907 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SEL RN NAME 1
E30 THROUGH E42 ASSIGNED

=> SEL RN NAME 2
E43 THROUGH E84 ASSIGNED

=> FILE CAPLUS MEDLINE USPATFULL WPID

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.70	40.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'CAPLUS' ENTERED AT 14:08:14 ON 25 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'MEDLINE' ENTERED AT 14:08:14 ON 25 JUN 2008

FILE 'USPATFULL' ENTERED AT 14:08:14 ON 25 JUN 2008

FILE 'WPIDS' ENTERED AT 14:08:14 ON 25 JUN 2008

```
=> S E30-E42
L7          176 (A-MONOCAPRYLIN/BI OR "(±)-GLYCEROL MONOCTANOATE"/BI
                OR "CAPRYLIC ACID A-MONOGLYCERIDE"/BI OR DL-1-MONOOCTANOIN
                /BI OR "GLYCERYL 1-MONOOCTANOATE"/BI OR MONOCTANOIN/BI OR "OCTAN
                OIC ACID 1-MONOGLYCERIDE"/BI OR 1-MONOCAPRYLIN/BI OR 1-MONOCAPRY
                LOYL-RAC-GLYCEROL/BI OR 1-MONOOCTANOIN/BI OR 1-MONOOCTANOYLGLYCE
                ROL/BI OR "2,3-DIHYDROXYPROPYL OCTANOATE"/BI OR 502-54-5/BI)

=> S E 43-E84
L8            0 E 43-E84

=> S E43-E84
   2 FILES SEARCHED...
L9       112094 (B-PYRIDINECARBOXAMIDE/BI OR AMINICOTIN/BI OR BENICOT/BI
                OR "DELONIN AMIDE"/BI OR DIPEGYL/BI OR "M-(AMINOCARBONYL)PYRIDIN
                E"/BI OR NAM/BI OR NIACINAMIDE/BI OR "NIAVIT PP"/BI OR NICAMINA/
                BI OR NICAMINDON/BI OR NICASIR/BI OR NICOBION/BI OR NICOFORT/BI
                OR "NICOSAN 2"/BI OR NICOSYLAMIDE/BI OR NICOTILAMIDE/BI OR NICOT
                INAMIDE/BI OR "NICOTINE ACID AMIDE"/BI OR "NICOTINIC ACID AMIDE"
                /BI OR "NICOTINIC AMIDE"/BI OR NICOTYLAMIDE/BI OR NICOVIT/BI OR
                NICOVITINA/BI OR NICTOAMIDE/BI OR NIOCINAMIDE/BI OR NIOZYMIN/BI
                OR "NSC 13128"/BI OR "NSC 27452"/BI OR PAPULEX/BI OR PELMIN/BI
                OR PELMINE/BI OR "PELONIN AMIDE"/BI OR VI-NICOTYL/BI OR "VITAMIN
                 B"/BI OR "VITAMIN B3"/BI OR "3-(AMINOCARBONYL)PYRIDINE"/BI OR
                3-AMIDOPYRIDINE/BI OR 3-CARBAMOYLPYRIDINE/BI OR 3-PYRIDINECARBOX
                AMIDE/BI OR "3-PYRIDINECARBOXYLIC ACID AMIDE"/BI OR 98-92-0/BI)

=> S L7 and L9
L10           9 L7 AND L9

=> DUP REM
ENTER L# LIST OR (END):L10
PROCESSING COMPLETED FOR L10
L11           9 DUP REM L10 (0 DUPLICATES REMOVED)

=> D L11 1-9 IBIB ABS

L11  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:1016569  CAPLUS
DOCUMENT NUMBER:          148:503081
TITLE:                    Novel drug delivery system
INVENTOR(S):              Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh
                          Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S):       Torrent Pharmaceuticals Limited, India
SOURCE:                   Indian Pat. Appl., 80pp., Addn. of Indian Appl. No.
                          2004MU198.
                          CODEN: INXXBQ
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     IN 2005MU01012       A     20070831    IN 2005-MU1012         20050826
PRIORITY APPLN. INFO.:                       IN 2004-MU198       A0 20040220
AB   A novel modified release dosage form comprising of a high solubility active
     ingredient, which utilizes dual retard technique to effectively reduce the
     quantity of release controlling agents.  Present invention can optionally
     comprise addnl. another active ingredient as an immediate release form or
```

modified release form. Present invention also relates to a process for preparing the said formulation.

L11 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2007:308290 USPATFULL
TITLE: Penetration Enhancer Combinations for Transdermal Delivery
INVENTOR(S): Mitragotri, Samir, Goleta, CA, UNITED STATES
Karande, Pankaj S., Somerville, MA, UNITED STATES
Jain, Amit K., Redwood City, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070269379	A1	20071122	
APPLICATION INFO.:	US 2004-560571	A1	20040721	(10)
	WO 2004-US23634		20040721	
			20070202	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-560717P	20030723 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rober Berliner, Berliner & Associated, 555 W. Fifth Street, 31st Floor, Los Angeles, CA, 90013, US
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 4179
AB A high throughput screening and isolation system identifies rare enhancer mixtures from a candidate pool of penetration enhancer combinations. The combinations are screened for high penetration but low irritation potential using a unique data mining method to find new potent and safe chemical penetration enhancer combinations. The members of a library of chemical penetration enhancer combinations are screened with a high throughput device to identify "hot spots", particular combinations that show higher chemical penetration enhancement compared to neighboring compositions. The irritation potentials of the hot spot combinations are measured to identify combinations that also show low irritation potential. A active component, such as a drug, is then combined with the combination in a formulation which is tested for the ability of the drug to penetrate into or through skin. It is then assessed whether the formulation can deliver the quantity of drug required, and animal tests are conducted to confirm in vivo the ability of the chemical penetration enhancer combinations to facilitate transport of sufficient active molecules across the skin to achieve therapeutic levels of the active molecule in the animal's blood. The invention provides specific unique and rare mixtures of chemical penetration enhancers that enhance skin permeability to hydrophilic macromolecules by more than 50-fold without inducing skin irritation, such as combinations of sodium laurel ether sulfate and 1-phenyl piperazine, and combinations of N-lauryl sarcosine and Span 20/sorbitan monolaurate.

L11 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2007:169566 USPATFULL
TITLE: Nucleic Acid-Based Matrixes
INVENTOR(S): LUO, Dan, Ithaca, NY, UNITED STATES
Li, Yougen, Pasadena, CA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 20070148246	A1	20070628
APPLICATION INFO.:	US 2006-464181	A1	20060811 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-722032P	20050929 (60)
	US 2006-783422P	20060317 (60)
	US 2006-783426P	20060317 (60)
	US 2005-707431P	20050811 (60)
	US 2006-745383P	20060421 (60)
	US 2006-756453P	20060105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 5559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2007:134496 USPATFULL
TITLE: Nucleic Acid-Based Matrixes for Protein Production
INVENTOR(S): LUO, Dan, Ithaca, NY, UNITED STATES
Um, Soong Ho, Ithaca, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070117177	A1	20070524
APPLICATION INFO.:	US 2006-464184	A1	20060811 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-722032P	20050929 (60)
	US 2006-783422P	20060317 (60)
	US 2006-783426P	20060317 (60)
	US 2005-707431P	20050811 (60)
	US 2006-745383P	20060421 (60)
	US 2006-756453P	20060105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 5584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include cell-free protein synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2007:134049 USPATFULL
TITLE:	Lyophilization process and products obtained thereby
INVENTOR(S):	Palepu, Nageswara R., Mill Creek, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070116729	A1	20070524
APPLICATION INFO.:	US 2005-282507	A1	20051118 (11)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Irving M. Fishman, c/o Cohen, Tauber, Spievack & Wagner, Suite 2400, 420 Lexington Avenue, New York, NY, 10170, US
NUMBER OF CLAIMS:	44
EXEMPLARY CLAIM:	1
LINE COUNT:	3917

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and/or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and/or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2006:21102 USPATFULL
TITLE:	Novel drug delivery system
INVENTOR(S):	Vaya, Navin, Gujarat, INDIA Karan, Rajesh Singh, Gujarat, INDIA Nadkarni, Sunil Sadanand, Gujarat, INDIA Gupta, Vinod Kumar, Gujarat, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060018934	A1	20060126
APPLICATION INFO.:	US 2005-134632	A1	20050519 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-630348, filed on 29 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2002-6982002	20020805
	IN 2002-6962003	20020805
	IN 2003-812003	20030122

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HEDMAN & COSTIGAN P.C., 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US
NUMBER OF CLAIMS:	60

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:21101 USPATFULL
TITLE: Novel drug delivery system
INVENTOR(S): Vaya, Navin, Gujarat, INDIA
Karan, Rajesh Singh, Gujarat, INDIA
Nadkarni, Sunil Sadanand, Gujarat, INDIA
Gupta, Vinod Kumar, Gujarat, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060018933	A1	20060126
APPLICATION INFO.:	US 2005-134631	A1	20050519 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-630348, filed on 29 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2002-6982002	20020805
	IN 2002-6962003	20020805
	IN 2003-812003	20030122

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HEDMAN & COSTIGAN P.C., 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:260886 USPATFULL
TITLE: Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
INVENTOR(S): Moneymaker, Ricky Dean, Stuart's Draft, VA, UNITED STATES
Klesman, Larry Scott, Lake Forest, IL, UNITED STATES
Theus, Jon Scott, Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 20050226907 A1 20051013
APPLICATION INFO.: US 2005-80790 A1 20050315 (11)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-868149, filed on 15 Jun 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2004-US19243	20040615
	US 2004-561097P	20040408 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: McAndrews Held and Malloy, Ltd., Suite 3400, 34th Floor, 500 W Madison, Chicago, IL, 60661, US
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 1934
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Individualized responsive dosing pharmanutrient systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses/effects. More specifically, a pharmanutrient system for generating individualized biological conditions/responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, organics substrates, inorganic or synthetic substrates, biological components, and/or other nutrients incorporated or provided with a pharmacologically active ingredient in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different pharmanutrient based on varying desired biological response within each dosing period.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2715 CAPLUS
DOCUMENT NUMBER: 140:53415
TITLE: Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
INVENTOR(S): Weidner, Morten Sloth
PATENT ASSIGNEE(S): Astion Development A/S, Den.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000333	A1	20031231	WO 2003-DK423	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491871	A1	20031231	CA 2003-2491871	20030620
AU 2003240441	A1	20040106	AU 2003-240441	20030620
EP 1560589	A1	20050810	EP 2003-729915	20030620

```
     EP 1560589          B1    20061004
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1674921          A     20050928    CN 2003-819661          20030620
     JP 2005537238       T     20051208    JP 2004-514590          20030620
     EP 1640011          A1    20060329    EP 2005-19961           20030620
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     AT 341334           T     20061015    AT 2003-729915          20030620
     NZ 537783           A     20061222    NZ 2003-537783          20030620
     ES 2274236          T3    20070516    ES 2003-729915          20030620
     NO 2005000309       A     20050318    NO 2005-309             20050119
     US 20060069131      A1    20060330    US 2005-517592          20050815
     HK 1076395          A1    20061124    HK 2005-110210          20051115
PRIORITY APPLN. INFO.:                      DK 2002-951        A    20020620
                                            US 2002-389879P    P    20020620
                                            EP 2003-729915     A3   20030620
                                            WO 2003-DK423      W    20030620
OTHER SOURCE(S):         MARPAT 140:53415
AB   The present invention relates to novel combinations of fatty acid derivs.
     and pyridine carboxy derivs., including fatty acid esters with glycerol
     and 3-carboxy pyridine derivs. such as niacinamide.  Such
     combinations have surprisingly shown antiviral and anti-microbial activity
     and the use for the treatment of inflammatory conditions and infections is
     disclosed herein.
REFERENCE COUNT:         17    THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> S  L7 and inflam?
L12         30 L7 AND INFLAM?

=> DUP REM
ENTER L# LIST OR (END):L12
PROCESSING COMPLETED FOR L12
L13          29 DUP REM L12 (1 DUPLICATE REMOVED)

=> D 28-29 IBIB ABS

L13  ANSWER 28 OF 29     MEDLINE on STN
ACCESSION NUMBER:   95230513     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 7714743
TITLE:              Absorption of transdermally delivered ketorolac acid in
                    humans.
AUTHOR:             Roy S D; Manoukian E; Combs D
CORPORATE SOURCE:   Syntex Research, Palo Alto, CA 94304.
SOURCE:             Journal of pharmaceutical sciences, (1995 Jan) Vol. 84, No.
                    1, pp. 49-52.
                    Journal code: 2985195R. ISSN: 0022-3549.
PUB. COUNTRY:       United States
DOCUMENT TYPE:      (CLINICAL TRIAL)
                    (IN VITRO)
                    Journal; Article; (JOURNAL ARTICLE)
                    (RANDOMIZED CONTROLLED TRIAL)
LANGUAGE:           English
FILE SEGMENT:       Priority Journals
ENTRY MONTH:        199505
ENTRY DATE:         Entered STN: 24 May 1995
                    Last Updated on STN: 3 Mar 2000
                    Entered Medline: 18 May 1995
AB   Transdermal delivery of ketorolac acid, a potent analgesic, through human
     skin in vitro and in vivo was evaluated.  The following three transdermal
```

solutions were selected to study the in vitro skin permeation rate of ketorolac acid: formulation A, isopropyl alcohol: water: isopropyl myristate (IPA/water/IPM; 11:7:1); formulation B, ethanol: propylene glycol:isopropyl myristate (ET/PG/IPM; 11:7:2); and formulation C, IPM/capmul (glyceryl mono- and dicaprylate; Monoctanoin). The permeation of ketorolac acid through cadaver skin from a saturated drug solution was evaluated at 32 degrees C with a modified Franz diffusion cell. The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively. The systemic bioavailability of ketorolac acid from three transdermal formulations was evaluated in nine healthy subjects in a randomized three-way crossover fashion. Hill Top chambers were used as prototype dermal delivery devices to load the drug solution. This procedure was followed by the immediate application of devices to human subjects for 24 h. Blood samples were collected at various time intervals up to 48 h, and the samples were assayed by HPLC. The basic pharmacokinetic parameters were derived from the drug plasma concentration versus time plot. The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively. Formulation A provided the highest in vitro and in vivo transdermal delivery rate among the three formulations studied. An excellent correlation between the in vitro steady-state skin flux and the area under the curve of in vivo plasma drug concentration versus time was observed for all the three formulations.

L13 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

ACCESSION NUMBER:	1991:12078 CAPLUS
DOCUMENT NUMBER:	114:12078
ORIGINAL REFERENCE NO.:	114:2119a,2122a
TITLE:	Topical effects of absorption enhancing agents on the rectal mucosa of rats in vivo
AUTHOR(S):	Van Hoogdalem, Ewoud J.; Vermeij-Kerrs, Christl; De Boer, Albertus G.; Breimer, Douwe D.
CORPORATE SOURCE:	Cent. Bio-Pharm. Sci., State Univ. Leiden, Leiden, 2300 RA, Neth.
SOURCE:	Journal of Pharmaceutical Sciences (1990), 79(10), 866-70 CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Attempts were made to assess the effects of cefoxitin formulations with various absorption promoters on mucosal integrity after rectal delivery in rats. On macroscopic and histol. evaluation, all drug formulations affected mucosal structure in terms of hyperemia, edema, loss of goblet cell vacuoles, detachment of enterocytes, and increase of the number of inflammatory cells; these effects were not reversible in 24 h. The effects of formulations with MGK (a mixture of glyceryl-1-monooctanoate, glyceryl-1,2-dioctanoate, glyceryl-1,3-dioctanoate, glyceryl trioctanoate, glycerol, and octanoic acid), monoglycerides, 3-amino-1-hydroxypropylidene-1,1-diphosphonate, and 4% (weight/volume) Na tauro-24,25-dihydrofusidate (STDHF) tended to exceed those observed with Na salicylate, medium-chain fatty acids, Azone, and lower STDHF concns. The clin. used suppository bases Witepsol H15 and PEG 1540/6000 and indomethacin suppositories also affected mucosal structure. Although the interanimal variability in scores was very substantial, results indicate that rectal absorption enhancement is associated with modification of paracellular transport after detachment of enterocytes. However, the extent of drug absorption enhancement appeared not to be directly related to the extent of mucosal damage.

=> D 20-27 IBIB ABS

L13 ANSWER 20 OF 29 USPATFULL on STN
ACCESSION NUMBER: 2001:90260 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20010002404	A1	20010531
	US 6576636	B2	20030610
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:753385 CAPLUS
DOCUMENT NUMBER: 132:15588
TITLE: Compositions and methods for topical delivery of oligonucleotides
INVENTOR(S): Mehta, Rahul; Hardee, Gregory E.; Cook, Phillip D.; Ecker, David J.; Tsai, Yali Jennifer; Templin, Michael V.
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9960167	A1	19991125	WO 1999-US11142	19990520
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2329252	A1	19991125	CA 1999-2329252	19990520
AU 9940069	A	19991206	AU 1999-40069	19990520
AU 753270	B2	20021010		

EP 1080226 A1 20010307 EP 1999-923252 19990520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2002515514 T 20020528 JP 2000-549773 19990520
PRIORITY APPLN. INFO.: US 1998-82336 A2 19980521
WO 1999-US11142 W 19990520

AB The present invention relates to compns. and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compns. include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 22 OF 29 USPATFULL on STN
ACCESSION NUMBER: 1998:98932 USPATFULL
TITLE: DHA-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 23 OF 29 USPATFULL on STN
ACCESSION NUMBER: 97:59168 USPATFULL
TITLE: Convertible microemulsion formulations
INVENTOR(S): Owen, Albert J., West Chester, PA, United States
Yiv, Seang H., Wilmington, DE, United States
PATENT ASSIGNEE(S): LDS Technologies, Inc., Boothwyn, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646109		19970708
APPLICATION INFO.:	US 1995-425475		19950420 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-885202, filed on 20 May 1992, now patented, Pat. No. US 5444041 which is a continuation-in-part of Ser. No. US 1992-841931, filed on 25 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-837347, filed on 14 Feb 1992, now abandoned which is a

continuation-in-part of Ser. No. US 1991-687691, filed on 19 Apr 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1992-US3086	19920415

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a water-in-oil (w/o) microemulsion which readily converts to an oil-in-water (o/w) emulsion by the addition of aqueous fluid to the w/o microemulsion, whereby any water-soluble biologically-active material in the aqueous phase is released for absorption by the body. The w/o microemulsion is particularly useful for storing proteins and the like for long periods of time at room temperature and above until they are ready for use, at which time the addition of aqueous fluid converts the microemulsion to an o/w emulsion and releases the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 24 OF 29 USPATFULL on STN
ACCESSION NUMBER: 97:44991 USPATFULL
TITLE: Convertible microemulsion formulations
INVENTOR(S): Owen, Albert J., West Chester, PA, United States
Yiv, Seang H., Wilmington, DE, United States
PATENT ASSIGNEE(S): LDS Technologies, Inc., Boothwyn, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5633226		19970527
APPLICATION INFO.:	US 1995-425787		19950420 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-885202, filed on 20 May 1992, now patented, Pat. No. US 5444041 which is a continuation-in-part of Ser. No. US 1992-841931, filed on 25 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-837347, filed on 14 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687691, filed on 19 Apr 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1992-US3086	19920415

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a water-in-oil (w/o) microemulsion which readily converts to an oil-in-water (o/w) emulsion by the addition of aqueous

fluid to the w/o microemulsion, whereby any water-soluble biologically-active material in the aqueous phase is released for absorption by the body. The w/o microemulsion is particularly useful for storing proteins and the like for long periods of time at room temperature and above until they are ready for use, at which time the addition of aqueous fluid converts the microemulsion to an o/w emulsion and releases the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 25 OF 29 USPATFULL on STN

ACCESSION NUMBER:	97:36218 USPATFULL
TITLE:	Disinfecting contact lenses
INVENTOR(S):	Isaacs, Charles E., 30 Devon Dr. North, Manalapan, NJ, United States 07726 Kim, Kwang S., 178 Dahlia St., Staten Island, NY, United States 10312 Thormar, Halldor, Langagerdi 15, Reykjavik, Iceland Heird, William C., 2001 Holcombe Blvd. Apt. 2701, Houston, TX, United States 77030 Wisniewski, Henryk M., 141 Nixon Ave., Staten Island, NY, United States 10304

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624958		19970429
APPLICATION INFO.:	US 1995-408079		19950322 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-58056, filed on 3 May 1993, now patented, Pat. No. US 5434182 which is a continuation of Ser. No. US 1992-896120, filed on 10 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-543111, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-365291, filed on 12 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-140078, filed on 31 Dec 1987, now patented, Pat. No. US 4997851

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Fay, Zohreh
LEGAL REPRESENTATIVE:	Kane, Dalsimer, Sullivan, Kurucz, Levy, Eisele and Richard
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
LINE COUNT:	725

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process of disinfecting a contact lens entails applying to the lens a mixture solution of an effective antimicrobial amount of a fatty acid, monoglyceride thereof or ether or lysophosphatidylcholine derivatives thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1996:161211 CAPLUS
DOCUMENT NUMBER:	124:185591
ORIGINAL REFERENCE NO.:	124:34167a,34170a
TITLE:	Controlled release oral drug delivery forms containing hydrogel-forming polymers
PATENT ASSIGNEE(S):	Yissum Research Development Co., Israel
SOURCE:	PCT Int. Appl., 35 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9534294	A1	19951221	WO 1995-US7519	19950613
W: AM, AT, AU, BB, BR, BY, CA, CH, CN, CZ, DE, DK, FI, GB, HU, JP, KP, RO, RU, SD, SE				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, ES, FR, GB, IT, LU, MC, SE, BF, BJ, MR, NE, SN, TD, TG				
IL 110024	A	19980405	IL 1994-110024	19940615
AU 9528270	A	19960105	AU 1995-28270	19950613
US 6692766	B1	20040217	US 1997-750674	19970228
US 20040185107	A1	20040923	US 2003-630918	20030731
US 20040219216	A1	20041104	US 2003-630917	20030731
US 7189414	B2	20070313		

PRIORITY APPLN. INFO.:

IL 1994-110024	A	19940615
WO 1995-US7519	W	19950613
US 1997-750674	A1	19970228

AB The present invention relates to a controlled-release drug delivery system comprising a drug which is susceptible to enzymic degradation by enzymes present in the intestinal tract and a polymeric matrix. The polymeric matrix which undergoes erosion in the gastrointestinal tract comprises a hydrogel-forming polymer selected from the group consisting of (a) polymers which are themselves capable of enhancing absorption of the drug across the intestinal mucosal tissues and of inhibiting degradation of the drug by intestinal enzymes and (b) polymers which are not themselves capable of enhancing absorption of the drug across the intestinal mucosal tissues and of inhibiting degradation of the drug by intestinal enzymes. The delivery system optionally further comprises an agent which enhances absorption of the drug across the intestinal mucosal tissues and/or an agent which inhibits degradation of the drug by intestinal enzymes. For example, bradykinin was incubated with 0.5% polycarbophil suspension, then α-chymotrypsin was added to the mixture and the incubation proceeded for addnl. 120 min. Almost no degradation of bradykinin was detected.

L13 ANSWER 27 OF 29 USPATFULL on STN
ACCESSION NUMBER: 95:75951 USPATFULL
TITLE: Convertible microemulsion formulations
INVENTOR(S): Owen, Albert J., West Chester, PA, United States
Yiv, Seang H., Wilmington, DE, United States
Sarkahian, Ani B., Bryn Mawr, PA, United States
PATENT ASSIGNEE(S): Ibah, Inc., Blue Bell, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5444041		19950822
APPLICATION INFO.:	US 1992-885202		19920520 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-841931, filed on 25 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-837347, filed on 14 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687691, filed on 19 Apr 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris
NUMBER OF CLAIMS: 137

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This is provided a water-in-oil (w/o) microemulsion which readily converts to an oil-in-water (o/w) emulsion by the addition of aqueous fluid to the w/o microemulsion, whereby any water-soluble biologically-active material in the aqueous phase is released for absorption by the body. The w/o microemulsion is particularly useful for storing proteins and the like for long periods of time at room temperature and above until they are ready for use, at which time the addition of aqueous fluid converts the microemulsion to an o/w emulsion and releases the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> S L7 and acne
L14 18 L7 AND ACNE

=> REM DUP
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

```
DELETE BIO?/Q           - delete query names starting with BIO
DELETE ?DRUG/A          - delete answer set names ending with DRUG
DELETE ?ELEC?/L         - delete L-number lists containing ELEC
DELETE ANTICOAG/S       - delete SDI request
DELETE ENZYME/B         - delete batch request
DELETE .MYCLUSTER       - delete user-defined cluster
DELETE .MYFORMAT        - delete user-defined display format
DELETE .MYFIELD         - delete user-defined search field
DELETE NAMELIST MYLIST - delete mailing list
```

To delete an ordered document or an offline print, enter its number.

Examples:

```
DELETE P123001C         - delete print request
DELETE D134002C         - delete document order request
```

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

```
DELETE L21              - delete a single L-number
DELETE L3-L6            - delete a range of L-numbers
DELETE LAST 4           - delete the last 4 L-numbers
DELETE L33-             - delete L33 and any higher L-number
```

```
  DELETE -L55           - delete L55 and any lower L-number
  DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                          renumber remaining L-numbers
  DELETE RENUMBER       - renumber L-numbers after deletion of
                          intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined
items, or E-numbers can be deleted.

Examples:

  DELETE SAVED/Q - delete all saved queries
  DELETE SAVED/A - delete all saved answer sets
  DELETE SAVED/L - delete all saved L-number lists
  DELETE SAVED   - delete all saved queries, answer sets,
                   and L-number lists
  DELETE SAVED/S - delete all SDI requests
  DELETE SAVED/B - delete all batch requests
  DELETE CLUSTER - delete all user-defined clusters
  DELETE FORMAT  - delete all user-defined display formats
  DELETE FIELD   - delete all user-defined search fields
  DELETE SELECT  - delete all E-numbers
  DELETE HISTORY - delete all L-numbers and restart the
                   session at L1

To delete an entire multifile SDI request, enter DELETE and
the name of the request.  To delete a component from the
multifile SDI, enter DELETE and the name of the component.

=> DUP REM L14
PROCESSING COMPLETED FOR L14
L15          18 DUP REM L14 (0 DUPLICATES REMOVED)

=> D 15-18 IBIB ABS

L15  ANSWER 15 OF 18  USPATFULL on STN
ACCESSION NUMBER:       1998:98932  USPATFULL
TITLE:                  DHA-pharmaceutical agent conjugates of taxanes
INVENTOR(S):            Shashoua, Victor E., Brookline, MA, United States
                        Swindell, Charles S., Merion, PA, United States
                        Webb, Nigel L., Bryn Mawr, PA, United States
                        Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S):     Neuromedica, Inc., Conshohocken, PA, United States
                        (U.S. corporation)

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 5795909              19980818
APPLICATION INFO.:      US 1996-651312          19960522  (8)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           Granted
PRIMARY EXAMINER:       Jarvis, William R. A.
LEGAL REPRESENTATIVE:   Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS:       12
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     27 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT:             2451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention provides conjugates of cis-docosahexaenoic acid and
       taxanes useful in treating cell proliferative disorders. Conjugates of
       paclitaxel and docetaxel are preferred.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:353836 CAPLUS
DOCUMENT NUMBER: 125:18690
ORIGINAL REFERENCE NO.: 125:3665a,3668a
TITLE: Combinations of wool wax acids and saturated glycerides for skin cleansing and treatment of mild acne and Propionibacterium acnes infection
INVENTOR(S): Traupe, Bernd; Wolf, Florian; Schoenrock, Uwe
PATENT ASSIGNEE(S): Beiersdorf A.-G., Germany
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 709082	A2	19960501	EP 1995-115283	19950928
EP 709082	A3	19980114		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
DE 4438588	A1	19960502	DE 1994-4438588	19941028
JP 08208450	A	19960813	JP 1995-297263	19951023

PRIORITY APPLN. INFO.: DE 1994-4438588 A 19941028
AB Combinations of wool wax acids and glycerol monoesters with monocarboxylic acids are useful in cosmetic or dermatol. compns. for cleansing the skin, treatment of mild forms of acne, and inhibition of Propionibacterium acnes. Thus, a roll-on gel contained ethoxylated hydrogenated castor oil 1.75, wool wax acids (150-200° fraction from mol. distillation at 0.1 bar) 0.40, α-glyceryl monocaprate 0.75, EtOH 62.00, perfume, and H2O to 100.00 weight%.

L15 ANSWER 17 OF 18 USPATFULL on STN
ACCESSION NUMBER: 95:101248 USPATFULL
TITLE: Spermicidal and cytocidal fatty acid compositions
INVENTOR(S): Isaacs, Charles E., Manalapan, NJ, United States
Kim, Kwang S., Staten Island, NY, United States
Wisniewski, Henryk M., Staten Island, NY, United States
PATENT ASSIGNEE(S): Research Foundation For Mental Health Hygiene, Inc., Albany, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5466714		19951114
APPLICATION INFO.:	US 1993-70086		19930528 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-896121, filed on 10 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-543111, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-365291, filed on 12 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-140078, filed on 31 Dec 1987, now patented, Pat. No. US 4997851
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prescott, Arthur C.
LEGAL REPRESENTATIVE: Kane, Dalsimer, Sullivan, Kurucz, Levy, Eisele and Richard
NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1
LINE COUNT: 1187
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to spermicidal or cytocidal activity of fatty acids and monoglycerides. More particularly, this invention is directed to the killing of sperm and cells by fatty acids and monoglycerides. The invention is also directed to spermicidal or cytocidal compositions consisting essentially of inert carrier and an effective amount of one or more compounds selected from the group consisting of fatty acids and monoglycerides thereof, fatty alcohols, and ether and lysophosphatidylcholine derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 18 OF 18 USPATFULL on STN
ACCESSION NUMBER: 95:64952 USPATFULL
TITLE: Antibacterial fatty acid compositions
INVENTOR(S): Isaacs, Charles E., 30 Devon Dr. North, Manalapan, NJ, United States 07726
Kim, Kwang S., 178 Dahlia St., Staten Island, NY, United States 10312
Thormar, Halldor, Langagerdi 15, Reykjavik, Iceland
Heird, William C., 2001 Holcombe Blvd., Apt. 2701, Houston, TX, United States 77030
Wisniewski, Henryk M., 141 Nixon Ave., Staten Island, NY, United States 10304

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5434182		19950718
APPLICATION INFO.:	US 1993-58056		19930503 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-896120, filed on 10 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-543111, filed on 25 Jun 1990 which is a continuation-in-part of Ser. No. US 1989-365291, filed on 12 Jun 1989 which is a continuation-in-part of Ser. No. US 1987-140078, filed on 31 Dec 1987, now patented, Pat. No. US 4997851
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Kane, Dalsimer, Sullivan, Kurucz, Levy, Eisele and Richard
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to antibacterial activity of fatty acids and monoglycerides. More particularly, this invention is directed to the killing of bacteria by fatty acids and monoglycerides. The invention is also directed to antibacterial pharmaceutical compositions consisting essentially of inert pharmaceutical carrier and an antibacterial effective amount of one or more compounds selected from the group consisting of fatty acids and monoglycerides thereof, fatty alcohols, and ethers and lysophosphatidylcholine derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> D 18 KWIC

L15 ANSWER 18 OF 18 USPATFULL on STN

DETD . . . serum by incubation
with monoglycerides at 37° C. for 30 min

Monoglyceride	Concn.sup.a in mg/ml (mM)	Reduction of virus titer (log.sub.10) VSV	HSV-1
Monocaprylin (8:0).sup.b	2.0 (9)	≥4.0	.sup. ND.sup.c
Monocaprin (10:0)	0.5 (2)	≥4.0	≥3.7
Monolaurin (12:0)	0.25 (0.9)	≥4.0	≥3.7
Monomyristin (14:0)	2.0 (13)	3.0.	. .

DETD Table 17 shows that when 1-monocapryloyl-rac-glycerol and 1-monodecanoyl-rac-glycerol monoglycerides are used with varying concentrations of sodium taurocholate, the 1-monodecanoyl-rac-glycerol is effective when used with concentrations as low as 2 mM sodium taurocholate whereas the 1-monocapryloyl-rac-glycerol needs at least 6 mM sodium taurocholate to be effective. The 1-monocapryloyl-rac-glycerol monoglyceride is still more likely to be used in a product, however, because it is more soluble.

DETD TABLE 22

Stability of white blood cells in whole human blood to added lipid

Sample	Concentration (mM)	Total White Blood Cells
Control	--	6.4
1-Monocapryloyl-rac-glycerol	15	2.4
1-O-Octyl-sn-glycerol	15	0.6
1-monodecanoyl-rac-glycerol	15	0.7
1-O-Decyl-sn-glycerol	15	1.31

DETD . . . Other potential applications disclosed for the spermicidal, antimicrobial, cytocidal, and antibacterial monoglycerides and fatty acids include: facial cream (as an acne treatment), bactericidal, fungicidal, virucidal; shampoo, hand lotion; athlete's foot medication (ointment, powder, soap); candies (for sore throat, bad breath, recurrent. . .

=> D 1-14 IBIB ABS

L15 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:769872 CAPLUS
DOCUMENT NUMBER: 148:387155
TITLE: Novel dosage form
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar

PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 96pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01013	A	20070629	IN 2005-MU1013	20050826
PRIORITY APPLN. INFO.:			IN 2005-MU1013	20050826

AB A dosage form comprising of a high-dose, high-solubility active ingredient for modified release and a low-dose active ingredient for immediate release wherein the weight ratio of immediate-release active ingredient and modified-release active ingredient is from 1:10 to 1:15000 and the weight of modified-release active ingredient per unit is from 500 mg to 1500 mg. A process for preparing the dosage form is provided.

L15 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1016569 CAPLUS
DOCUMENT NUMBER: 148:503081
TITLE: Novel drug delivery system
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826
PRIORITY APPLN. INFO.:			IN 2004-MU198 A0	20040220

AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

L15 ANSWER 3 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2007:308290 USPATFULL
TITLE: Penetration Enhancer Combinations for Transdermal Delivery
INVENTOR(S): Mitragotri, Samir, Goleta, CA, UNITED STATES
Karande, Pankaj S., Somerville, MA, UNITED STATES
Jain, Amit K., Redwood City, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070269379	A1	20071122	
APPLICATION INFO.:	US 2004-560571	A1	20040721	(10)
	WO 2004-US23634		20040721	
			20070202	PCT 371 date

	NUMBER	DATE

PRIORITY INFORMATION: US 2003-560717P 20030723 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rober Berliner, Berliner & Associated, 555 W. Fifth Street, 31st Floor, Los Angeles, CA, 90013, US
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 4179

AB A high throughput screening and isolation system identifies rare enhancer mixtures from a candidate pool of penetration enhancer combinations. The combinations are screened for high penetration but low irritation potential using a unique data mining method to find new potent and safe chemical penetration enhancer combinations. The members of a library of chemical penetration enhancer combinations are screened with a high throughput device to identify "hot spots", particular combinations that show higher chemical penetration enhancement compared to neighboring compositions. The irritation potentials of the hot spot combinations are measured to identify combinations that also show low irritation potential. A active component, such as a drug, is then combined with the combination in a formulation which is tested for the ability of the drug to penetrate into or through skin. It is then assessed whether the formulation can deliver the quantity of drug required, and animal tests are conducted to confirm in vivo the ability of the chemical penetration enhancer combinations to facilitate transport of sufficient active molecules across the skin to achieve therapeutic levels of the active molecule in the animal's blood. The invention provides specific unique and rare mixtures of chemical penetration enhancers that enhance skin permeability to hydrophilic macromolecules by more than 50-fold without inducing skin irritation, such as combinations of sodium laurel ether sulfate and 1-phenyl piperazine, and combinations of N-lauryl sarcosine and Span 20/sorbitan monolaurate.

L15 ANSWER 4 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2007:107489 USPATFULL
TITLE: Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
INVENTOR(S): Rogers, Robin D., Tuscaloosa, AL, UNITED STATES
Daly, Daniel T., Tuscaloosa, AL, UNITED STATES
Swatloski, Richard P., Tuscaloosa, AL, UNITED STATES
Hough, Whitney L., Albertville, AL, UNITED STATES
Davis, James Hilliard JR., Mobile, AL, UNITED STATES
Smiglak, Marcin, Tuscaloosa, AL, UNITED STATES
Pernak, Juliusz, Poznan, POLAND
Spear, Scott K., Bankston, AL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070093462	A1	20070426	
APPLICATION INFO.:	US 2006-545938	A1	20061010	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-764850P	20060202 (60)
	US 2005-724604P	20051007 (60)
	US 2005-724605P	20051007 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 PEACHTREE STREET, ATLANTA, GA, 30309-3915, US
NUMBER OF CLAIMS: 193
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 7075
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:100738 CAPLUS
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20060024365	A1	20060202	US 2005-134633		20050519
IN 2002MU00697	A	20040529	IN 2002-MU697		20020805
IN 193042	A1	20040626			
IN 2002MU00699	A	20040529	IN 2002-MU699		20020805
IN 2003MU00080	A	20050204	IN 2003-MU80		20030122
IN 2003MU00082	A	20050204	IN 2003-MU82		20030122
US 20040096499	A1	20040520	US 2003-630446		20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A	20020805
			IN 2002-MU699	A	20020805
			IN 2003-MU80	A	20030122
			IN 2003-MU82	A	20030122
			US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

L15 ANSWER 6 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2006:27536 USPATFULL
TITLE: Novel dosage form
INVENTOR(S): Vaya, Navin, Gujarat, INDIA
Karan, Rajesh Singh, Gujarat, INDIA
Sadanand, Sunil, Gujarat, INDIA

Gupta, Vinod Kumar, Gujarat, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060024365	A1	20060202
APPLICATION INFO.:	US 2005-134633	A1	20050519 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-630446, filed on 29 Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2002-6992002	20020805
	IN 2002-6972002	20020805
	IN 2003-802003	20030122
	IN 2003-822003	20030122

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HEDMAN & COSTIGAN P.C., 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US
NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2006:21102 USPATFULL
TITLE: Novel drug delivery system
INVENTOR(S): Vaya, Navin, Gujarat, INDIA
Karan, Rajesh Singh, Gujarat, INDIA
Nadkarni, Sunil Sadanand, Gujarat, INDIA
Gupta, Vinod Kumar, Gujarat, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060018934	A1	20060126
APPLICATION INFO.:	US 2005-134632	A1	20050519 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-630348, filed on 29 Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2002-6982002	20020805
	IN 2002-6962003	20020805
	IN 2003-812003	20030122

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HEDMAN & COSTIGAN P.C., 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2006:21101 USPATFULL
TITLE: Novel drug delivery system
INVENTOR(S): Vaya, Navin, Gujarat, INDIA
Karan, Rajesh Singh, Gujarat, INDIA
Nadkarni, Sunil Sadanand, Gujarat, INDIA
Gupta, Vinod Kumar, Gujarat, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060018933	A1	20060126
APPLICATION INFO.:	US 2005-134631	A1	20050519 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-630348, filed on 29 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2002-6982002	20020805
	IN 2002-6962003	20020805
	IN 2003-812003	20030122

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HEDMAN & COSTIGAN P.C., 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:233875 USPATFULL
TITLE: DHA-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor E., Brookline, MA, UNITED STATES
Swindell, Charles E., Merion, PA, UNITED STATES
Webb, Nigel L., Bryn Mawr, PA, UNITED STATES
Bradley, Matthews O., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Protarga, Inc., King of Prussia, PA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040180949	A1	20040916
	US 7199151	B2	20070403
APPLICATION INFO.:	US 2003-618884	A1	20030714 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-846838, filed on 1 May		

2001, GRANTED, Pat. No. US 6602902 Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 10 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:139413 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, UNITED STATES
Bradley, Matthews O., Laytonsville, MD, UNITED STATES
Swindell, Charles S., Merion, PA, UNITED STATES
Shashoua, Victor E., Brookline, MA, UNITED STATES
PATENT ASSIGNEE(S): Protarga Pharmaceuticals, Inc., King of Prussia, PA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040106589	A1	20040603
APPLICATION INFO.:	US 2003-455250	A1	20030605 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-730450, filed on 5 Dec 2000, GRANTED, Pat. No. US 6576636 Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2715 CAPLUS
DOCUMENT NUMBER: 140:53415
TITLE: Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
INVENTOR(S): Weidner, Morten Sloth
PATENT ASSIGNEE(S): Astion Development A/S, Den.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000333	A1	20031231	WO 2003-DK423	20030620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2491871	A1	20031231	CA 2003-2491871	20030620
AU 2003240441	A1	20040106	AU 2003-240441	20030620
EP 1560589	A1	20050810	EP 2003-729915	20030620
EP 1560589	B1	20061004		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1674921	A	20050928	CN 2003-819661	20030620
JP 2005537238	T	20051208	JP 2004-514590	20030620
EP 1640011	A1	20060329	EP 2005-19961	20030620
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
AT 341334	T	20061015	AT 2003-729915	20030620
NZ 537783	A	20061222	NZ 2003-537783	20030620
ES 2274236	T3	20070516	ES 2003-729915	20030620
NO 2005000309	A	20050318	NO 2005-309	20050119
US 20060069131	A1	20060330	US 2005-517592	20050815
HK 1076395	A1	20061124	HK 2005-110210	20051115

PRIORITY APPLN. INFO.:		
DK 2002-951	A	20020620
US 2002-389879P	P	20020620
EP 2003-729915	A3	20030620
WO 2003-DK423	W	20030620

OTHER SOURCE(S): MARPAT 140:53415

AB The present invention relates to novel combinations of fatty acid derivs. and pyridine carboxy derivs., including fatty acid esters with glycerol and 3-carboxy pyridine derivs. such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed herein.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:85867 USPATFULL
TITLE: Oral delivery formulation
INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES
Solari, Nancy E., West Newton, MA, UNITED STATES
Flangan, Margaret A., Stow, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030059471	A1	20030327
APPLICATION INFO.:	US 2001-997277	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69501P	19971215 (60)
	US 1998-73867P	19980204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 2950
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Flakes containing drugs and methods for forming and using such flakes are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 13 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:17328 USPATFULL
TITLE: Dha-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES
Swindell, Charles, Merion, PA, UNITED STATES
Webb, Nigel, Bryn Mawr, PA, UNITED STATES
Bradley, Matthews, Layton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020010208	A1	20020124
	US 6602902	B2	20030805
APPLICATION INFO.:	US 2001-846838	A1	20010501 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 14 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2001:90260 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20010002404	A1	20010531
	US 6576636	B2	20030610

APPLICATION INFO.: US 2000-730450 A1 20001205 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> END
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	374.36	415.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.00	-8.80

STN INTERNATIONAL LOGOFF AT 14:28:53 ON 25 JUN 2008